NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Clovis Oncology Inc (NASDAQ: CLVS)

 
CLVS Technical Analysis
5
As on 5th Aug 2022 CLVS SHARE Price closed @ 1.66 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.84 & Strong Sell for SHORT-TERM with Stoploss of 6.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

CLVSSHARE Price

Open 1.61 Change Price %
High 1.74 1 Day 0.02 1.22
Low 1.61 1 Week -0.06 -3.49
Close 1.66 1 Month -0.08 -4.60
Volume 4091100 1 Year -5.02 -75.15
52 Week High 7.86 | 52 Week Low 0.63
 
NASDAQ USA Most Active Stocks
AMD 102.31 -1.54%
MRKR 0.54 63.64%
DKNG 17.96 9.78%
AAPL 165.35 -0.28%
OPEN 5.72 21.70%
BBBY 8.16 32.68%
AMZN 140.80 -1.24%
LYFT 20.28 16.62%
GOVX 3.22 -9.80%
ENDP 0.72 12.50%
 
NASDAQ USA Top Gainers Stocks
REDU 3.41 1075.86%
USWS 5.60 508.70%
NDRAW 0.03 200.00%
GLSPT 33.43 138.62%
BCAC 22.71 125.30%
GPCOR 0.15 114.29%
GSMGW 0.02 100.00%
FTVIW 0.22 83.33%
GBRGR 0.12 71.43%
PTOCW 0.17 70.00%
 
NASDAQ USA Top Losers Stocks
PTRAW 0.23 -89.59%
CREXW 0.04 -55.56%
MILEW 0.06 -53.85%
HSDT 0.48 -52.94%
BTAQW 0.01 -50.00%
ALACW 0.01 -50.00%
HYZNW 0.37 -49.32%
ACBAW 0.08 -46.67%
ALACR 0.04 -42.86%
IKNX 19.52 -42.42%
 
 
CLVS
Daily Charts
CLVS
Intraday Charts
Whats New @
Bazaartrend
CLVS
Free Analysis
 
CLVS Important Levels Intraday
RESISTANCE1.91
RESISTANCE1.83
RESISTANCE1.78
RESISTANCE1.73
SUPPORT1.59
SUPPORT1.54
SUPPORT1.49
SUPPORT1.41
 
CLVS Forecast August 2022
4th UP Forecast9.19
3rd UP Forecast6.78
2nd UP Forecast5.28
1st UP Forecast3.79
1st DOWN Forecast-0.47
2nd DOWN Forecast-1.96
3rd DOWN Forecast-3.46
4th DOWN Forecast-5.87
 
CLVS Weekly Forecast
4th UP Forecast4.13
3rd UP Forecast3.34
2nd UP Forecast2.85
1st UP Forecast2.36
1st DOWN Forecast0.96
2nd DOWN Forecast0.47
3rd DOWN Forecast-0.02
4th DOWN Forecast-0.81
 
CLVS Forecast2022
4th UP Forecast17.79
3rd UP Forecast12.62
2nd UP Forecast9.42
1st UP Forecast6.22
1st DOWN Forecast-2.9
2nd DOWN Forecast-6.1
3rd DOWN Forecast-9.3
4th DOWN Forecast-14.47
 
 
CLVS Other Details
Segment EQ
Market Capital 518635808.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
CLVS Address
CLVS
 
CLVS Latest News
 
Your Comments and Response on Clovis Oncology Inc
 
CLVS Business Profile
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company distributes its products primarily through specialty pharmacies and distributors to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, and Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. The company was incorporated in 2009 and is headquartered in Boulder, Colorado. Address: 5500 Flatiron Parkway, Boulder, CO, United States, 80301
 
2005-2021 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service